Immutep Faces Class Action Lawsuit; Investors May Claim Losses
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 40 minutes ago
0mins
Should l Buy IMMP?
Source: Globenewswire
- Class Action Initiated: Bragar Eagel & Squire has filed a class action lawsuit against Immutep on behalf of investors who purchased American Depositary Receipts between March 24, 2025, and March 12, 2026, indicating potential misleading statements that could affect investor rights.
- Allegation Details: The lawsuit claims that Immutep concealed critical data regarding the TACTI-004 clinical trial, asserting strong progress while significant risks existed, leading to investor losses once the truth was revealed.
- Investor Action Deadline: Affected investors must apply by July 6, 2026, to be appointed as lead plaintiffs in the lawsuit, highlighting the urgency and importance of legal proceedings for protecting their interests.
- Law Firm Background: Bragar Eagel & Squire is a nationally recognized law firm specializing in shareholder rights and securities litigation, underscoring its expertise and influence in investor protection matters.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IMMP?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IMMP
Wall Street analysts forecast IMMP stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.503
Low
12.00
Averages
12.00
High
12.00
Current: 0.503
Low
12.00
Averages
12.00
High
12.00
About IMMP
Immutep Limited is an Australia-based late-stage biotechnology company. The Company is focused on developing novel immunotherapies for cancer and autoimmune disease. It is focused on advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3’s ability to stimulate or suppress the immune response. Its lead clinical candidate is eftilagimod alfa (efti or IMP321) for the treatment of different types of cancers. Efti is the Company’s first-in-class novel immunotherapy that directly activates the immune system to fight cancer, which is under evaluation in TACTI-004 (KEYNOTE-F91), a registrational Phase III trial for the first-line therapy of advanced or metastatic non-small cell lung cancer. Its second in-house product candidate (IMP761) which is in clinical development for the treatment of autoimmune disease, a third product candidate, IMP731, a depleting antibody that could remove T cells involved in autoimmunity.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Immutep Faces Class Action Lawsuit; Investors May Claim Losses
- Class Action Initiated: Bragar Eagel & Squire has filed a class action lawsuit against Immutep on behalf of investors who purchased American Depositary Receipts between March 24, 2025, and March 12, 2026, indicating potential misleading statements that could affect investor rights.
- Allegation Details: The lawsuit claims that Immutep concealed critical data regarding the TACTI-004 clinical trial, asserting strong progress while significant risks existed, leading to investor losses once the truth was revealed.
- Investor Action Deadline: Affected investors must apply by July 6, 2026, to be appointed as lead plaintiffs in the lawsuit, highlighting the urgency and importance of legal proceedings for protecting their interests.
- Law Firm Background: Bragar Eagel & Squire is a nationally recognized law firm specializing in shareholder rights and securities litigation, underscoring its expertise and influence in investor protection matters.
See More
Class Action Lawsuit Announced for Immutep ADRs
- Class Action Initiation: Rosen Law Firm has filed a class action lawsuit on behalf of investors who purchased Immutep ADRs between March 24, 2025, and March 12, 2026, allowing potential lead plaintiffs to apply by July 6, 2026, indicating the legal process is underway.
- Compensation Potential: Investors joining the class action may be entitled to compensation without any upfront costs, which reduces the financial burden on investors and encourages more affected parties to participate in the lawsuit.
- Lawsuit Background: The lawsuit alleges that Immutep made false or misleading statements during the TACTI-004 trial, concealing the true status of the trial, which led to investor losses when the actual information was disclosed, highlighting the company's lack of transparency in clinical trials.
- Law Firm Reputation: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and influence in handling similar cases.
See More
Class Action Lawsuit Announced for Immutep Ltd. ADRs
- Class Action Initiation: Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of American Depositary Receipts (ADRs) of Immutep Ltd. (NASDAQ: IMMP) from March 24, 2025, to March 12, 2026, indicating potential misleading statements by the company during this period that led to investor losses.
- Compensation Mechanism: Investors participating in the lawsuit may receive compensation without any out-of-pocket costs, highlighting a risk-free legal avenue for investors to seek financial redress, thereby enhancing investor confidence in the process.
- Lawsuit Background: The lawsuit alleges that Immutep concealed critical clinical data regarding the TACTI-004 trial, resulting in investor losses once the true information was revealed, indicating a lack of transparency in clinical trials that could impact the company's future financing capabilities.
- Law Firm's Credentials: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and effectiveness in handling such cases, which may attract more investors to join the lawsuit.
See More
Immutep Faces Class Action Lawsuit Impacting Stock Price
- Class Action Filed: Pomerantz LLP has initiated a class action lawsuit against Immutep, alleging securities fraud and other unlawful business practices by the company and certain officers, with investors advised to apply as Lead Plaintiff by July 6, 2026, highlighting significant legal risks to the company's reputation.
- Trial Discontinuation: On March 13, 2026, Immutep announced the discontinuation of the TACTI-004 Phase III study based on the Independent Data Monitoring Committee's recommendation following a futility analysis, which may necessitate major adjustments in the company's future R&D direction and impact its market competitiveness.
- Stock Price Plunge: Following the trial discontinuation announcement, Immutep's American Depositary Receipt (ADR) price plummeted by $2.27, or 82.44%, closing at $0.48, reflecting extreme pessimism in the market regarding the company's future prospects.
- Legal Affairs Impact: Pomerantz LLP is a prominent firm in securities class action litigation, and its established reputation in handling securities fraud cases may significantly influence Immutep's legal strategy and future development trajectory.
See More
Important Date Reminder for Immutep ADRs Lawsuit
- Lawsuit Deadline: Investors must file a motion by July 6, 2026, to seek lead plaintiff status in the Immutep Limited (NASDAQ: IMMP) ADRs lawsuit, emphasizing the need for timely action to protect their interests.
- Stock Price Impact: Following the March 13, 2026 announcement that the Independent Data Monitoring Committee recommended discontinuing the TACTI-004 Phase III trial, Immutep's ADRs plummeted approximately $2.28 per share, reflecting an 83% single-day decline that severely undermined investor confidence.
- Importance of Lead Plaintiff Role: Under the Private Securities Litigation Reform Act of 1995, the lead plaintiff represents the interests of all shareholders, and while appointment does not guarantee higher individual recovery, it allows for direct oversight of the litigation process to align with the majority's interests.
- Rights of Absent Class Members: Investors who do not seek lead plaintiff status can still participate in any recovery without taking action before the deadline, ensuring that all investors retain their rights in the lawsuit and are not excluded due to missed applications.
See More
Immutep Faces Class Action Lawsuit Over Securities Violations
- Class Action Filed: Bronstein, Gewirtz & Grossman LLC has initiated a class action lawsuit against Immutep, seeking damages for investors who purchased securities between March 24, 2025, and March 12, 2026, highlighting concerns over potential investor losses.
- Allegations of Misrepresentation: The complaint alleges that Immutep concealed and misrepresented the status and prospects of its TACTI-004 trial, particularly relying on previous positive results to create an unfounded optimism, severely impacting investor confidence in the company's future.
- Legal Deadlines and Implications: Investors must apply by July 6, 2026, to be appointed as lead plaintiffs to participate in potential recoveries, underscoring the importance of legal processes in protecting investor rights.
- Law Firm Credentials: Bronstein, Gewirtz & Grossman LLC is recognized for recovering hundreds of millions for investors, emphasizing its expertise in securities fraud class actions and its commitment to providing legal support for affected investors.
See More
Immutep Faces Class Action Lawsuit; Investors May Claim Losses
- Class Action Initiated: Bragar Eagel & Squire has filed a class action lawsuit against Immutep on behalf of investors who purchased American Depositary Receipts between March 24, 2025, and March 12, 2026, indicating potential misleading statements that could affect investor rights.
- Allegation Details: The lawsuit claims that Immutep concealed critical data regarding the TACTI-004 clinical trial, asserting strong progress while significant risks existed, leading to investor losses once the truth was revealed.
- Investor Action Deadline: Affected investors must apply by July 6, 2026, to be appointed as lead plaintiffs in the lawsuit, highlighting the urgency and importance of legal proceedings for protecting their interests.
- Law Firm Background: Bragar Eagel & Squire is a nationally recognized law firm specializing in shareholder rights and securities litigation, underscoring its expertise and influence in investor protection matters.
See More
Class Action Lawsuit Announced for Immutep ADRs
- Class Action Initiation: Rosen Law Firm has filed a class action lawsuit on behalf of investors who purchased Immutep ADRs between March 24, 2025, and March 12, 2026, allowing potential lead plaintiffs to apply by July 6, 2026, indicating the legal process is underway.
- Compensation Potential: Investors joining the class action may be entitled to compensation without any upfront costs, which reduces the financial burden on investors and encourages more affected parties to participate in the lawsuit.
- Lawsuit Background: The lawsuit alleges that Immutep made false or misleading statements during the TACTI-004 trial, concealing the true status of the trial, which led to investor losses when the actual information was disclosed, highlighting the company's lack of transparency in clinical trials.
- Law Firm Reputation: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and influence in handling similar cases.
See More
Class Action Lawsuit Announced for Immutep Ltd. ADRs
- Class Action Initiation: Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of American Depositary Receipts (ADRs) of Immutep Ltd. (NASDAQ: IMMP) from March 24, 2025, to March 12, 2026, indicating potential misleading statements by the company during this period that led to investor losses.
- Compensation Mechanism: Investors participating in the lawsuit may receive compensation without any out-of-pocket costs, highlighting a risk-free legal avenue for investors to seek financial redress, thereby enhancing investor confidence in the process.
- Lawsuit Background: The lawsuit alleges that Immutep concealed critical clinical data regarding the TACTI-004 trial, resulting in investor losses once the true information was revealed, indicating a lack of transparency in clinical trials that could impact the company's future financing capabilities.
- Law Firm's Credentials: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and effectiveness in handling such cases, which may attract more investors to join the lawsuit.
See More
Immutep Faces Class Action Lawsuit Impacting Stock Price
- Class Action Filed: Pomerantz LLP has initiated a class action lawsuit against Immutep, alleging securities fraud and other unlawful business practices by the company and certain officers, with investors advised to apply as Lead Plaintiff by July 6, 2026, highlighting significant legal risks to the company's reputation.
- Trial Discontinuation: On March 13, 2026, Immutep announced the discontinuation of the TACTI-004 Phase III study based on the Independent Data Monitoring Committee's recommendation following a futility analysis, which may necessitate major adjustments in the company's future R&D direction and impact its market competitiveness.
- Stock Price Plunge: Following the trial discontinuation announcement, Immutep's American Depositary Receipt (ADR) price plummeted by $2.27, or 82.44%, closing at $0.48, reflecting extreme pessimism in the market regarding the company's future prospects.
- Legal Affairs Impact: Pomerantz LLP is a prominent firm in securities class action litigation, and its established reputation in handling securities fraud cases may significantly influence Immutep's legal strategy and future development trajectory.
See More
Important Date Reminder for Immutep ADRs Lawsuit
- Lawsuit Deadline: Investors must file a motion by July 6, 2026, to seek lead plaintiff status in the Immutep Limited (NASDAQ: IMMP) ADRs lawsuit, emphasizing the need for timely action to protect their interests.
- Stock Price Impact: Following the March 13, 2026 announcement that the Independent Data Monitoring Committee recommended discontinuing the TACTI-004 Phase III trial, Immutep's ADRs plummeted approximately $2.28 per share, reflecting an 83% single-day decline that severely undermined investor confidence.
- Importance of Lead Plaintiff Role: Under the Private Securities Litigation Reform Act of 1995, the lead plaintiff represents the interests of all shareholders, and while appointment does not guarantee higher individual recovery, it allows for direct oversight of the litigation process to align with the majority's interests.
- Rights of Absent Class Members: Investors who do not seek lead plaintiff status can still participate in any recovery without taking action before the deadline, ensuring that all investors retain their rights in the lawsuit and are not excluded due to missed applications.
See More
Immutep Faces Class Action Lawsuit Over Securities Violations
- Class Action Filed: Bronstein, Gewirtz & Grossman LLC has initiated a class action lawsuit against Immutep, seeking damages for investors who purchased securities between March 24, 2025, and March 12, 2026, highlighting concerns over potential investor losses.
- Allegations of Misrepresentation: The complaint alleges that Immutep concealed and misrepresented the status and prospects of its TACTI-004 trial, particularly relying on previous positive results to create an unfounded optimism, severely impacting investor confidence in the company's future.
- Legal Deadlines and Implications: Investors must apply by July 6, 2026, to be appointed as lead plaintiffs to participate in potential recoveries, underscoring the importance of legal processes in protecting investor rights.
- Law Firm Credentials: Bronstein, Gewirtz & Grossman LLC is recognized for recovering hundreds of millions for investors, emphasizing its expertise in securities fraud class actions and its commitment to providing legal support for affected investors.
See More
